Previous Article | Next Article ![]()
Journal of Clinical Microbiology, November 1998, p. 3205-3210, Vol. 36, No. 11
School of Hygiene and Public Health and
School of Medicine, The Johns Hopkins University, Baltimore,
Maryland1;
Cayetano Heredia University,
Lima, Peru;2
National Institute of
Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, Maryland3; and
Womack Army
Medical Center, Fort Bragg, North Carolina4
Received 13 April 1998/Returned for modification 8 June
1998/Accepted 3 August 1998
Trichomonas vaginalis infection is the most prevalent
nonviral sexually transmitted disease (STD) in the world. A PCR test using vaginal swab samples for the detection of T. vaginalis was developed to add T. vaginalis infection
to the growing list of STDs that can be detected by DNA amplification
techniques. A primer set, BTUB 9/2, was designed to target a
well-conserved region in the beta-tubulin genes of T. vaginalis. All strains (15 of 15) of T. vaginalis
tested were successfully detected by PCR giving a single predicted
product of 112 bp in gel electrophoresis. No such targeted product was
amplified with DNA from Trichomonas tenax,
Trichomonas gallinae, Chlamydia
trachomatis, Neisseria gonorrhoeae, Giardia
lamblia, Chilomastix sulcatus, Dientamoeba fragilis, and Entamoeba histolytica. An optimal
analytical sensitivity of one T. vaginalis organism per PCR
was achieved. Culture, performed with the Inpouch TV culture system,
was examined daily with a light microscope to identify T. vaginalis. Twenty-three of 350 (6.6%) vaginal swab samples from
women attending an army medical clinic were culture positive for
T. vaginalis. Of these culture positive specimens, PCR
detected 22 of 23 (96%) with primer set BTUB 9/2, and wet preparation
detected only 12 of 23 (52%). Seventeen specimens were BTUB
9/2-PCR positive and culture negative. Ten of these discordant
specimens were determined to be as true positive by PCR using primer
sets TVA 5-1/6 and/or AP65 A/B, which target different regions in the
T. vaginalis genome, and seven were determined to be false
positive. The sensitivity of BTUB 9/2-PCR was 97% and the specificity
was 98%. The sensitivities of culture and wet preparation were 70 and
36%, respectively. The diagnosis of T. vaginalis infection by PCR is a sensitive and specific
method that could be incorporated into a joint strategy for the
screening of multiple STDs by using molecular amplification
methods.
Trichomonas vaginalis
infection is the most prevalent nonviral sexually transmitted disease
in the world (18). In the United States, an estimated 3 million woman contract trichomoniasis every year (12).
Symptomatic women with trichomoniasis usually complain of vaginal
discharge, vulvovaginal soreness, and/or irritation. Dysuria and
dyspareunia are also common (18, 21). T. vaginalis can be asymptomatic in 10 to 50% of women
(9, 28). The organism can be recovered in 11% of men
attending sexually transmitted disease (STD) clinics (13)
and from 30 to 60% of male sexual partners of infected women, usually
as a self-limited mild urethritis (9, 13). It can be
transmitted to neonates during passage through an infected birth
canal (2 to 17%), but the infection is usually asymptomatic and self
limited (4). The incidence of trichomoniasis is highest in
women with multiple partners and in groups with a high prevalence of
other STDs (3). Whether trichomoniasis is a risk factor for
human immunodeficiency virus transmission or just a marker for
high-risk heterosexual activity remains unclear (15). An
association of pelvic inflammatory disease, tubal infertility, and
cervical cancer with previous episodes of trichomoniasis has been
reported but may be explained by its association with other STDs
(16, 17, 29). Complications of trichomonal vaginitis that
have been reported include premature rupture of membranes, premature
labor, low birth weight, and post-abortion or post-hysterectomy
infection (2, 8, 9, 21, 22).
Traditionally physicians make the diagnosis based on clinical grounds,
but in women, the characteristics of the vaginal discharge, including
color and odor, are poor predictors of T. vaginalis (21, 23). Since no symptom alone
or in combination is sufficient to diagnose T. vaginalis infection reliably, laboratory diagnosis is
necessary (28). T. vaginalis may
be identified in vaginal secretions by using a wet preparation, but
this method is only 35 to 80% sensitive compared with culture
(6, 14). The sensitivity of wet preparation is highly
dependent on the expertise of the microscopist (9) and the
prompt transport and laboratory processing of samples before the
organism becomes lysed or loses motility. Other diagnostic techniques,
such as fluorescent antibody (14), enzyme-linked
immunosorbent assay (20), and a hybridization test
(5), have been used to detect T. vaginalis and have had reported sensitivities between
70 and 90% (14). Culture in microaerophilic conditions is
estimated to be 85 to 95% sensitive and has been considered the
"gold standard" for diagnosis (9).
In this study, a PCR targeting the beta-tubulin genes of T. vaginalis was developed for the detection of the
organism in vaginal swab samples. The targeted genes encode the amino
acid sequence of beta-tubulin protein (11), a major
component of the T. vaginalis cytoskeleton.
Trichomonas PCR was compared with culture and wet preparation.
Discrepant results were adjudicated by PCR using a previously described
set of primers (19) and a set of primers targeting the
adhesin genes of T. vaginalis. Since
elevated pH of vaginal secretions in patients infected with
T. vaginalis has been reported
(21), its utility as a predictor was also explored in
this study.
T. vaginalis strains.
One
strain from the American Type Culture Collection (Manassas, Va.) (ATCC
SF-314 030001) and 14 strains of T. vaginalis (designated A to N) isolated by culture of
vaginal secretions from patients attending an STD clinic were used to
assess the sensitivity of the PCR primer sets. The specificity was
evaluated by testing other related Trichomonas spp.,
flagellates, amoebae, or cervicovaginal pathogens (Trichomonas
tenax ATCC 30207, Trichomonas gallinae ATCC 30002, Giardia lamblia ATCC SF-741 30888, Chilomastix
sulcatus ATCC 50562, Dientamoeba fragilis ATCC 30948, Entamoeba histolytica ATCC SF-31-90015, Chlamydia
trachomatis serovar E ATCC VR 3488, and Neisseria
gonorrhoeae ATCC 19424).
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Diagnosis of Trichomonas vaginalis
Infection by PCR Using Vaginal Swab Samples
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
70°C.
Clinical specimens. Informed consent was obtained from all study participants. Before insertion of the speculum, clinicians collected vaginal swab samples (n = 350) from women attending the Epidemiology and Disease Control Clinic at the Womack Army Medical Center, Fort Bragg, N.C., from March to December 1997. The median age of the sampled population was 24 (range, 18 to 47), and 30% were Caucasian, 64% were African American, and 6% were of other races.
Vaginal swab samples were placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample, and the preparation was mixed, incubated at room temperature for 10 min, and stored at
70°C until tested.
A second vaginal swab sample was obtained after the insertion of the
speculum. It was immediately touched to a glass slide together with a
drop of normal saline for the microscopic (×100) wet examination of
trichomonas in vaginal fluid. After the wet preparation was made, the
swab was immediately inoculated into the Inpouch TV culture system
(Biomed Diagnostics, Santa Clara, Calif.) (6). The Inpouch
culture bag was sealed, incubated at 30°C, and examined daily with a
light microscope to identify T. vaginalis.
The pH of vaginal secretions was measured by using pH test strips
(Sigma).
PCR primers. A set of primers targeting a conserved region of the beta-tubulin genes of T. vaginalis (btub1, -2, and -3) was designed, synthesized, and tested. The sequences were as follows: for BTUB 9, 5' CAT TGA TAA CGA AGC TCT TTA CGA T 3' (positions 850 to 874); and for BTUB 2, 5' GCA TGT TGT GCC GGA CAT AAC CAT 3' (positions 961 to 938).
The DNA sequences for the primer set BTUB 9/2 were designed to target conserved regions of the three beta-tubulin genes of T. vaginalis to improve the analytical sensitivity (GenBank accession numbers: btub1, L05468; btub2, L05469; and btub3, L05470). In addition, to improve specificity, these DNA sequences were selected from the regions of the T. vaginalis beta-tubulin genes that differed substantially from the beta-tubulin gene sequences of humans and other microorganisms. (GenBank accession numbers: G. lamblia, X06748; Trypanosoma brucei subsp. rhodesiense, K02836; Trypanosoma cruzi, M97956; Toxoplasma gondii, M20025; Homo sapiens, V00598 J00317; and Plasmodium falciparum, G9981) (Fig. 1).
|
PCR. PCR was performed with 10 µl of cultures (including all T. vaginalis strains and the other microorganisms mentioned above) processed by the Chelex method, or with 50 µl of vaginal swab samples processed with AMPLICOR specimen buffers. PCRs were performed in an automated thermocycler (Perkin-Elmer Cetus, Norwalk, Conn.). The final reaction mixture (100 µl) contained 25 pmol of each primer, 2.5 mM deoxynucleoside triphosphate, 1× PCR buffer (10 mM Tris HCl [pH 8.4], 50 mM KCl), and 2 U of AmpliTaq Gold DNA polymerase (Perkin-Elmer Cetus) overlaid with 2 drops of mineral oil. Since 1.0 mM MgCl2 is a component of the AMPLICOR specimen buffers, 1.5 mM MgCl2 was added to the reaction mixture; otherwise, 2.5 mM MgCl2 was used when cultures of microorganisms processed with Chelex were tested.
A touchdown method for thermal cycling was used. Cycling times were 75 s at 95°C followed by 60 cycles of denaturation temperature 95°C for 45 s, annealing temperature beginning at 62°C and ending at 52°C for 45 s, and extension temperature of 72°C for 1 min. The annealing temperature was lowered one degree every four cycles until reaching 52°C, and this annealing temperature was then kept until the end of the cycling process. To avoid product carryover, PCRs were set up in a room separate from all activities involving amplified target sequences, including thermocycling areas, PCR product storage, and gel electrophoresis. A separate set of pipetting devices was devoted to the setup of PCRs, and aerosol barrier pipette tips were used. Negative controls, including uninoculated transport media, were used throughout the specimen preparation and PCR process. A low copy number (n = 50/PCR) of trichomonas as positive control was included in every PCR run.Detection of amplified targets. The primer set BTUB 9/2 was designed to amplify a DNA product of 112 bp from the three beta-tubulin genes (Fig. 1). Primer set TVA 5-1/6 amplified a DNA product of 98 bp from a segment of the T. vaginalis genome (102-bp clone A6p). Primer set AP65 A/B amplified a DNA product of 209 bp from both ap65-1 and -2 adhesin genes of T. vaginalis (sequence numbers 304 to 512).
Twenty microliters of amplified product was electrophoresed at 120 V in 12% polyacrylamide gels in Tris-borate-EDTA buffer and stained with ethidium bromide (0.01 mM). The sizes of the amplified products were assessed by comparison with a commercial 50-bp weight marker (XIII; Boehringer Mannheim, Indianapolis, Ind.).Adjudication of discrepant results and statistical analysis. Discrepant specimens (those found to be culture negative and PCR positive) were determined to be T. vaginalis positive by performing PCR with other primer sets (TVA 5-1/6 and AP65 A/B). The gold standard was considered to be either culture positivity or PCR positivity with primer set BTUB 9/2 and at least one other primer set (TVA 5-1/6 or AP65 A/B). Sensitivity and specificity were calculated by using the defined gold standard. Confidence intervals for sensitivity and specificity were determined based on a normal approximation to the binomial distribution. Agreement between PCR and culture was assessed by using the kappa test (7).
| |
RESULTS |
|---|
|
|
|---|
Primer set BTUB 9/2 amplified the predicted 112-bp product in all 15 T. vaginalis strains tested. The analytical sensitivity of PCR with primer set BTUB 9/2 on the twofold dilutions of T. vaginalis organisms was the amplification of the DNA of one organism per PCR (see Fig. 3). No targeted PCR products were amplified when DNAs from other vaginal pathogens or protozoa were tested with the BTUB 9/2 primer set. However, a slightly bigger product (125 bp) was obtained (in gel electrophoresis) when DNA from the oral T. tenax was tested.
PCR primer sets TVA 5-1/6 and AP65 A/B, which were used to resolve discrepant results in our clinical study, amplified the predicted 98-bp product in 14 of 15 strains of T. vaginalis and the predicted 209-bp product in 15 of 15 strains of T. vaginalis, respectively. Neither primer set TVA 5-1/6 (Fig. 2) nor primer set TVA 5/6 (not modified) amplified one particular clinical strain of T. vaginalis (strain L). None of the other vaginal pathogens or protozoa tested was detected by primer sets TVA 5-1/6 or AP65 A/B. The DNA corresponding to one copy of T. vaginalis (strain M) was amplified by both sets of primers TVA 5-1/6 (Fig. 3) and AP65 A/B (data not shown).
|
|
Twenty-three of 350 vaginal swab samples (6.6%) were culture positive for T. vaginalis. Wet preparation detected 52% (12 of 23), and BTUB 9/2 PCR detected 96% (22 of 23) of these positive cultures. Seventeen specimens were BTUB 9/2 PCR positive and culture negative. Ten of these discrepant specimens were determined to be true positives by PCR with primer sets TVA 5-1/6 and/or AP65 A/B targeting different regions in the T. vaginalis genome, and seven could not be confirmed as positives and were considered false positives (Table 1). Primer set TVA5-1/6 detected 61% (13 of 23) of specimens positive by culture. Primer set AP65 A/B detected 4 of 9 (44%) positive cultures that were not detected by PCR with TVA 5-1/6, and 6 of 10 (60%) negative cultures detected positive by two or more PCR primer sets (Table 1). Three specimens that were found to be positive by wet preparation could not be confirmed positive by culture or PCR with any of the primer sets tested and were deemed false positives.
|
After resolving discrepant results that were culture negative and PCR
positive, the sensitivity of PCR with the primer set BTUB 9/2 was 97%
(32 of 33; 95% confidence interval [CI], 95.2 to 98.8), and the
specificity was 98% (310 of 317; 95% CI, 96.3 to 99.3) (Table
2). The sensitivity of culture was 70%
(23 of 33; 95% CI, 64.9 to 74.5) and the specificity was 100% (317 of 317). The sensitivity of wet preparation was 36% (12 of 33; 95% CI,
31.3 to 41.4) and the specificity was 99% (314 of 317; 95% CI, 98 to
100). Although culture and the PCR with primer set TVA 5-1/6 had
the same sensitivity and specificity (Table 2), their agreement was
only moderate (
= 0.58). In comparison, there was substantial
agreement between culture and PCR with primer set BTUB 9/2 (
= 0.78). The prevalence of T. vaginalis in
this STD population was 9.4% (33 of 350) after the adjudication of
discrepant results.
|
A similar proportion of confirmed trichomonas-positive patients was symptomatic (24 of 33 [72.7%]) compared to patients who were negative for trichomonas (230/317 [72.6%]) (P = 0.9). Sixty-seven percent (22 of 33) of confirmed T. vaginalis-positive patients had vaginal secretions of pH of >4.5 compared to 43% (136 of 317) of negative patients (P = 0.009). The odds ratio of having a trichomonas infection was 2.7 (95% CI, 1.3 to 5.6) when pH was >4.5. In this study, treatment for trichomoniasis was provided according to clinic standard methods on the basis of wet preparation results. In a retrospective analysis, 52% (17 of 33) of patients with confirmed trichomonas infections received appropriate treatment with metronidazole at the clinic site, five of them because bacterial vaginosis was suspected. In addition, no diagnosis or treatment was given to 15% (5 of 33) of infected patients even though three had genitourinary symptoms (Table 3).
|
| |
DISCUSSION |
|---|
|
|
|---|
Trichomonas PCR with primer set BTUB 9/2 was 97% sensitive and 98% specific. It was more sensitive than wet preparation or culture. One culture-positive specimen could not be detected by any of the three PCR primer sets and was assumed to be a true positive by definition. The number of confirmed T. vaginalis-positive samples was increased by 39% by PCR compared to culture (32 of 350 [9.1%] versus 23 of 350 [6.6%]). PCR with primer set BTUB 9/2 for the detection of T. vaginalis had good analytical sensitivity and was able to amplify one trichomonas organism per PCR. The predicted DNA product (112 bp) in the targeted beta-tubulin gene was amplified with all T. vaginalis strains tested (15 of 15). The analytical specificity of primer set BTUB 9/2 was optimal, since no targeted DNA products were detected with other protozoa or vaginal pathogens.
In the T. vaginalis genome, there are several copies of the three genes encoding beta-tubulin proteins (beta-tubulin 1, 2, and 3) (11). Primer set BTUB 9/2 was designed to target a well-conserved region in all three beta-tubulin genes, thus improving sensitivity because of increased number of DNA target copies available for amplification. This region appears to be moderately conserved across other trichomonas species, because a slightly bigger PCR product of 125 bp was amplified by primer set BTUB 9/2 when DNA from the oral T. tenax was tested but not with DNA from T. gallinae. Although the 125-bp product detected with DNA of T. gallinae is similar in size to the product of T. vaginalis (112 bp), which could be difficult to differentiate by standard gel electrophoresis, specificity should not be affected since each Trichomonas species appears to be limited to its specific site of colonization (T. tenax inhabits the mouth and T. vaginalis only the genital and urinary tracts) (13).
The specificity of the primers depends on the annealing temperature, with higher temperatures favoring higher specificity. The use of a touchdown protocol increased the specificity of the PCR by favoring the amplification of targeted copies of DNA amplified during early cycles at higher annealing temperatures and eliminating spurious products. The DNA polymerase used (AmpliTaq Gold) is not active until heated to 95°C, thus simulating a hot-start PCR technique. The use of this enzyme also avoided erroneous amplification of DNA products due to nonspecific annealing of primers at lower temperatures.
In our study, PCR with primer set TVA 5-1/6 detected 61% (14 of
23) of culture-positive specimens. In previous studies, when compared
with culture, PCR with primer set TVA 5/6 detected 90% (44 of
49) of culture-positive distal vaginal swab samples from an STD clinic
in Pittsburgh, Pa. (10), and detected 91% (41 of 45) of
culture-positive tampon specimens collected from a population of the
Torres Strait Island (24). The target sequence of primer set TVA 5/6 is the full length of the 102-bp A6p clone isolated by
Riley et al. from the T. vaginalis genome
with the restriction enzyme Sau3A (recognition sequence,
GATC [the arrow indicates the cleavage site]) (19).
Since both TVA5 and TVA6 primers included this recognition sequence
at the 5' end, we designed the primer TVA 5-1, which excluded the
GATC sequence, to avoid the formation of primer dimers during
amplification. This slight modification is unlikely to explain the
difference in the proportion of positive cultures detected by PCR with
primer set TVA 5-1/6 compared to previous studies with primer
set TVA 5/6 (not modified). A possible explanation for this
difference is that a genetically more diverse group of
T. vaginalis strains were represented in
the population of our study, which differed in the targeted region of
primer set TVA 5/6 and were not detected. This conclusion is
supported by the failure of primer sets TVA 5-1/6
or TVA 5/6 to detect T. vaginalis strain L.
The Chelex method for DNA preparation from cultures was simple, inexpensive, and easy to perform and prevented contamination as a result of manipulation of specimens used in other DNA preparation methods. As chelating resin, Chelex 100 has been used to extract heavy metals from solutions and, when used for DNA extraction, may also eliminate PCR inhibitors present in the samples and/or prevent the disruption of the genomic DNA as suggested by Walsh et al. (25).
Vaginal swab samples for the PCR screening of T. vaginalis are adequate and are comparable to posterior vaginal vault specimens collected with a speculum during a pelvic examination (27). In our study, the vaginal swab samples were collected by the clinicians, but self-administered vaginal swab samples, which are practical, rapid, and easy to obtain, can also be used for screening. Other studies have demonstrated that self-administered vaginal swab samples are comparable to physician-administered samples for the PCR detection of trichomonal infection (26).
An increased pH of the vaginal secretions in patients infected with T. vaginalis has been previously reported (21). In our study, two-thirds of the patients with confirmed positive T. vaginalis infection had vaginal secretion pHs of >4.5. Nevertheless, these patients represented only 16% of the total number of patients with elevated pHs, making pH an inadequate predictor for trichomonas infection.
Retrospectively, only 36% of patients with confirmed T. vaginalis infection were diagnosed by wet preparation, only 52% received appropriate treatment with metronidazole at the clinic, and no clinical diagnosis or treatment was given to 15% of the infected patients. These findings suggest the need for a more accurate diagnostic test for trichomonas, such as PCR, to prevent complications, transmission to sexual partners, and asymptomatic carriers, and to decrease possible transmission of HIV (2, 8, 9, 15, 21, 22).
Although wet preparation had minimal cost, its sensitivity is highly dependent on the expertise of the microscopist (9), prompt transport, and laboratory processing before the organism lyses or loses motility. In our study, even when the wet preparation was performed at the collection site, its sensitivity (36%) was suboptimal compared to PCR. Culture had a better sensitivity (70%) than wet mount examination but required more time for laboratory turnaround since cultures are held for 1 week. PCR results are available in 2 to 3 days and provided the highest sensitivity. The cost of PCR testing comes mainly from the cost of reagents, which is about two dollars per specimen, approximately equivalent to the cost of an Inpouch TV culture bag. The technician time is probably equivalent since cultures require daily examination by light microscopy. Although trichomonas PCR requires more technical skill, molecular amplification techniques are currently in use in many laboratories for the detection of C. trachomatis and N. gonorrhoeae infections. Thus, trichomonas PCR could easily be incorporated into the work flow of other diagnostic amplification procedures.
Vaginal swab samples for trichomonas PCR were transported in and processed with AMPLICOR specimen buffers, which is the transport and processing method for the C. trachomatis-N. gonorrhoeae PCR test (AMPLICOR, Roche Diagnostic System) currently in research use in our laboratory. Preliminary results indicate that 2 sucrose phosphate, which is a common chlamydia culture transport medium, is also an adequate transport media for this trichomonas PCR method, as well as for the C. trachomatis-N. gonorrhoeae PCR test, as suggested by the manufacturer. Thus, specimens transported in 2 sucrose phosphate media can be subsequently processed by the Chelex method. Incorporating PCR with BTUB 9/2 for T. vaginalis into the routine laboratory diagnostic methods using the same processed sample used for the PCR detection of C. trachomatis and N. gonorrhoeae could be a cost-effective strategy when screening programs for multiple STDs are implemented.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by grant #DAMD17-96-1-6309, U.S. Army Medical Research and Material Command, Fort Detrick, Md. 21702.
We thank Marie Tenant and the clinicians at the EDC for their collaboration in specimen collection; Jessie Chou, Kimberly Crotchfelt, and Anna Sierra-Honinman for laboratory assistance; and Katherine Kacena, Anita Kacena, M. Atenas, and Diana Perkins for assistance with preparation of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: The Johns Hopkins University, Infectious Disease Division, 1154 Ross Research Bldg., 720 Rutland Ave., Baltimore, MD 21205. Phone: (410) 614-0932. Fax: (410) 614-9775. E-mail: cgaydos{at}welchlink.welch.jhu.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Alderete, J. F., J. L. O'Brien, R. Arroyo, J. A. Engbring, O. Musatovova, O. Lopez, C. Lauriano, and J. Nguyen. 1995. Cloning and molecular characterization of two genes encoding adhesion proteins involved in Trichomonas vaginalis cytoadherence. Mol. Microbiol. 17:69-83[Medline]. |
| 2. | Coth, M. F., J. G. Pastorek, R. P. Nugent, S. H. Hiller, R. S. Gibbs, D. H. Martin, D. A. Eschebach, R. Edelman, J. H. Carey, J. A. Regan, M. A. Krohn, M. A. Klebanoff, A. Vijaya Rao, G. G. Rhoads, and the Vaginal Infections and Prematurity Study Group. 1997. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex. Transm. Dis. 24:353-360[Medline]. |
| 3. |
Coth, M. F.,
J. G. Pastorek,
R. P. Nugent,
D. E. Yerg,
D. H. Martin,
D. A. Eschenbach, et al.
1991.
Demographic and behavioral predictors of Trichomonas vaginalis infection among pregnant women.
Obstet. Gynecol.
78:1087-1092 |
| 4. | Danesh, I. S., J. M. Stephen, and J. Gorbach. 1995. Neonatal Trichomonas vaginalis infection. J. Emerg. Med. 13:51-54[Medline]. |
| 5. | DeMeo, L. R., D. L. Draper, J. A. McGregor, D. F. Moore, C. R. Peter, P. S. Kapernick, and W. M. McCormack. 1996. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am. J. Obstet. Gynecol. 174:1339-1342[Medline]. |
| 6. |
Draper, D.,
R. Parker,
E. Patterson,
W. Jones,
M. Beutz,
J. French,
K. Borchardt, and J. McGregor.
1993.
Detection of Trichomonas vaginalis in pregnant women with the InPouch TV culture system.
J. Clin. Microbiol.
31:1016-1018 |
| 7. | Fleiss, J. L. 1981. Statistical methods for rates and proportions, 2nd ed. John Wiley and Sons, New York, N.Y. |
| 8. | Hardy, P. H., J. B. Hardy, E. E. Nell, D. A. Graham, M. R. Spence, and R. C. Rosenbaum. 1984. Prevalence of six sexually transmitted disease agents among pregnant inner-city adolescents and pregnancy outcome. Lancet ii:333-337. |
| 9. | Heine, P., and J. A. McGregor. 1993. Trichomonas vaginalis: a reemerging pathogen. Clin. Obstet. Gynecol. 36:137-144[Medline]. |
| 10. | Heine, R. P., H. C. Wiesenfeld, R. L. Sweet, and S. S. Witkin. 1997. Polymerase chain reaction analysis of distal vaginal specimens: a less invasive strategy for detection of Trichomonas vaginalis. Clin. Infect. Dis. 24:985-987[Medline]. |
| 11. |
Katiyar, S. K., and T. D. Edlind.
1994.
-tubulin genes of Trichomonas vaginalis.
Mol. Biochem. Parasitol.
64:33-42[Medline].
|
| 12. | Kent, H. L. 1991. Epidemiology of vaginitis. Am. J. Obstet. Gynecol. 165:1168-1176[Medline]. |
| 13. | Krieger, J. N. 1995. Trichomoniasis in men: old issues and new data. Sex. Transm. Dis. 22:83-96[Medline]. |
| 14. | Krieger, J. N., M. R. Tam, C. E. Stevens, I. O. Nielsen, J. H. Hale, N. B. Kiviat, and K. K. Holmes. 1988. Diagnosis of trichomoniasis: comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA 259:1223-1227[Abstract]. |
| 15. | Laga, M., A. Manoka, M. Kivuvu, B. Malele, M. Tuliza, N. Nzila, J. Goeman, F. Behets, V. Batter, M. Alary, W. L. Heyward, R. W. Rider, and P. Piot. 1993. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 7:95-102[Medline]. |
| 16. | Okonofua, F. E., K. A. Ako-Nai, and M. D. Dighitoghi. 1995. Lower genital tract infection in infertile Nigerian women compared with controls. Genitourin. Med. 71:163-168[Medline]. |
| 17. | Paisarntantiwong, R., S. Brockmann, L. Clarke, S. Landesman, J. Feldman, and H. Minkoff. 1995. The relationship of vaginal trichomoniasis and pelvic inflammatory disease among women colonized with Chlamydia trachomatis. Sex. Transm. Dis. 22:344-347[Medline]. |
| 18. | Rein, M. F. 1995. Trichomonas vaginalis, p. 2493-2497. In G. L. Mandell, J. E. Bennet, and R. Dolin (ed.), Principles and practices of infection disease. Churchill Livingston, New York, N.Y. |
| 19. |
Riley, D. E.,
M. C. Roberts,
T. Takayama, and J. N. Krieger.
1992.
Development of a polymerase chain reaction-based diagnosis of Trichomonas vaginalis.
J. Clin. Microbiol.
30:465-472 |
| 20. | Sharma, P., N. Malla, I. Gupta, N. K. Ganguly, and R. C. Mahajan. 1991. A comparison of wet mount, culture and enzyme linked immunosorbent assay for the diagnosis of trichomoniasis in women. Trop. Geogr. Med. 43:257-260[Medline]. |
| 21. |
Sobel, J. D.
1996.
Vaginitis.
N. Engl. J. Med.
337:1896-1903 |
| 22. | Soper, D. E., R. C. Bump, and W. G. Hurt. 1990. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am. J. Obstet. Gynecol. 163:1016-1021[Medline]. |
| 23. | Spence, M. R., D. H. Hollander, J. Smith, L. McCaig, D. Sewel, and M. Brockman. 1980. The clinical and laboratory diagnosis of Trichomonas vaginalis infection. Sex. Transm. Dis. 7:168-171[Medline]. |
| 24. | Tabrizi, S. N., B. Paterson, C. K. Fairley, F. J. Bowden, and S. M. Garland. 1997. A self-administered technique for the detection of sexually transmitted diseases in remote communities. J. Infect. Dis. 176:289-292[Medline]. |
| 25. | Walsh, P. S., D. A. Metzger, and R. Higuchi. 1991. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. BioTechniques 10:506-513[Medline]. |
| 26. | Wawer, M. J., D. McNairn, F. Wabwire-Mangen, L. Paxton, R. H. Gray, and N. Kiwanuka. 1995. Self-administered vaginal swabs for population-based assessment of Trichomonas vaginalis prevalence. Lancet 345:131-132[Medline]. (Letter.) |
| 27. | Witkin, S. S., S. R. Inglis, and M. Polaneczky. 1996. Detection of Chlamydia trachomatis and Trichomonas vaginalis by polymerase chain reaction in introital specimens from pregnant women. Am. J. Obstet. Gynecol. 175:165-167[Medline]. |
| 28. | Wolner-Hanssen, P., J. N. Krieger, C. E. Steven, N. B. Kiviat, L. Koustsky, C. Mcritchlow, T. De Roven, S. Hillier, and K. K. Holmes. 1989. Clinical manifestation of vaginal trichomoniasis. JAMA 264:571-576. |
| 29. | Zhang, Z. F., S. Graham, S. Z. Yu, et al. 1995. Trichomonas vaginalis and cervical cancer: a prospective study in China. Ann. Epidemiol. 5:325-332[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|